Search results for " Effector"

showing 9 items of 29 documents

The role of death effector domain (DED)-containing proteins in acute oxidative cell injury in hepatocytes

2012

Abstract Apoptosis is a mechanism that regulates hepatic tissue homeostasis and contributes to both acute and chronic injury in liver disease. The apoptotic signaling cascade involves activation of the death-inducing signaling complex (DISC) and subsequent recruitment of proteins containing death effector domains (DED), which regulate downstream effector molecules. Prominent among these are the Fas-associated death domain (FADD) and the cellular caspase 8-like inhibitory protein (cFLIP), and alterations in these proteins can lead to severe disruption of physiological processes, including acute liver failure or hepatocellular carcinoma. Their role in cell signaling events independent of the …

MAPK/ERK pathwayProgrammed cell deathDeath Domain Receptor Signaling Adaptor ProteinsbiologyBlotting WesternBiochemistryArticleCell biologyMiceMicroscopy FluorescencePhysiology (medical)Cell Line TumorDeath-inducing signaling complexModels Animalbiology.proteinHepatocytesAnimalsHumansDeath effector domainFADDSignal transductionCaspaseDeath domainSignal Transduction
researchProduct

Regulating TRAIL Receptor-Induced Cell Death at the Membrane: A Deadly Discussion

2011

Article Open access plus; International audience; The use of TRAIL/APO2L and monoclonal antibodies targeting TRAIL receptors for cancer therapy holds great promise, due to their ability to restore cancer cell sensitivity to apoptosis in association with conventional chemotherapeutic drugs in a large variety of tumors. TRAIL-induced cell death is tightly regulated right from the membrane and at the DISC (Death-Inducing Signaling Complex) level. The following patent and literature review aims to present and highlight recent findings of the deadly discussion that determines tumor cell fate upon TRAIL engagement.

MESH: Cell DeathMESH: Signal TransductionCancer ResearchApoptosisTRAILMESH : Models BiologicalscaffoldCell membrane0302 clinical medicineDrug DiscoveryMESH: AnimalsPharmacology (medical)Receptordeath effector domain0303 health sciencesCell DeathGeneral MedicineTRAIL-R4.3. Good healthCell biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisSignal transductionMESH : Apoptosis Regulatory ProteinsSignal TransductionProgrammed cell deathc-FLIPdeath domainmedicine.drug_classMESH : Cell MembraneCancer therapyBiologyMonoclonal antibodyModels BiologicalArticle03 medical and health sciencesmedicineAnimalsHumansChemotherapy[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyMESH: Receptors TNF-Related Apoptosis-Inducing LigandMESH : Receptors TNF-Related Apoptosis-Inducing Ligand[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular Biology030304 developmental biologyMESH : Signal TransductionMESH: HumansMESH: Apoptosis Regulatory ProteinsMESH: ApoptosisMESH : HumansCell MembraneMESH: Models BiologicalDISCReceptors TNF-Related Apoptosis-Inducing LigandApoptosisMESH : Cell DeathFADDCancer cellMESH : AnimalsApoptosis Regulatory ProteinsMESH : ApoptosisMESH: Cell MembraneRecent Patents on Anti-Cancer Drug Discovery
researchProduct

Direct Evidence for Viral Antigen Presentation during Latent Cytomegalovirus Infection

2021

Murine models of cytomegalovirus (CMV) infection have revealed an immunological phenomenon known as “memory inflation” (MI). After a peak of a primary CD8+ T-cell response, the pool of epitope-specific cells contracts in parallel to the resolution of productive infection and the establishment of a latent infection, referred to as “latency.” CMV latency is associated with an increase in the number of cells specific for certain viral epitopes over time. The inflationary subset was identified as effector-memory T cells (iTEM) characterized by the cell surface phenotype KLRG1+CD127−CD62L−. As we have shown recently, latent viral genomes are not transcriptionally silent. Rather, viral genes are …

Microbiology (medical)Adoptive cell transferAntigenicitylatent infectionTransgeneAntigen presentationCongenital cytomegalovirus infectionBiologymedicine.disease_causeEpitopeviral latencymedicineImmunology and AllergyMolecular BiologycytomegalovirusMutationGeneral Immunology and MicrobiologyBrief ReportRmedicine.diseaseVirologyantigen presentationInfectious Diseasesmemory inflation (MI)Medicineinflationary effector-memory CD8 T cells (iTEM)CD8Pathogens
researchProduct

Salmonella bongori Provides Insights into the Evolution of the Salmonellae

2011

The genus Salmonella contains two species, S. bongori and S. enterica. Compared to the well-studied S. enterica there is a marked lack of information regarding the genetic makeup and diversity of S. bongori. S. bongori has been found predominantly associated with cold-blooded animals, but it can infect humans. To define the phylogeny of this species, and compare it to S. enterica, we have sequenced 28 isolates representing most of the known diversity of S. bongori. This cross-species analysis allowed us to confidently differentiate ancestral functions from those acquired following speciation, which include both metabolic and virulence-associated capacities. We show that, although S. bongori…

Salmonellamedicine.disease_causeSettore MED/42 - Igiene Generale E ApplicataTranslocation GeneticEnteropathogenic Escherichia coli1108 Medical MicrobiologySalmonellaCOMPLETE GENOME SEQUENCEIII SECRETION SYSTEMBiology (General)PATHOGENICITY ISLAND 2PhylogenyGenetics0303 health sciencesbiologyVirulenceEffectorPARASITOLOGYENTERICA SEROVAR TYPHIMURIUMSalmonella entericaGenomicsSalmonella bongori evolutionary genomicsBiological EvolutionUREIDOGLYCOLLATE LYASEInfectious DiseasesSalmonella enterica1107 ImmunologyQR180MedicineKLEBSIELLA-PNEUMONIAELife Sciences & BiomedicineResearch Article0605 MicrobiologySalmonella bongoriMICROBIOLOGYESCHERICHIA-COLI K-12Genomic IslandsQH301-705.5Sequence analysisVirulence FactorsImmunologyVirulenceVIROLOGYENCODED EFFECTORsalmonella; salmonella bongori; evoluzione geneticaMicrobiologyQH30103 medical and health sciencesVirologyGeneticsmedicineMICROARRAY ANALYSISAnimalsHumansEnteropathogenic Escherichia coliBiologyMolecular BiologyGene030304 developmental biologyEvolutionary BiologyScience & Technology030306 microbiologyANTIBIOTIC-RESISTANCESequence Analysis DNARC581-607biology.organism_classificationGenes BacterialImmunologic diseases. Allergy
researchProduct

Prognostic Impact of let-7e MicroRNA and Its Target Genes in Localized High-Risk Intestinal GIST: A Spanish Group for Research on Sarcoma (GEIS) Study

2020

MicroRNAs (miRNAs) are small non-coding RNAs that negatively regulate gene expression at the post-transcriptional level, and they have been described as being associated with tumor prognosis. Here, miRNA profiling was planned to explore new molecular prognostic biomarkers in localized intestinal high-risk GIST. Paraffin tumor blocks of 14 and 86 patients were used in the discovery and expansion sets, respectively. GeneChip miRNA v3.0 was employed to identify the miRNAs differentially expressed between relapsed and non-relapsed patient samples, which were validated in the expansion set, by qRT-PCR. RT2 Profiler PCR Array was used for the screening of let-7e targets. Expression levels were co…

caspase-3Cancer Research<i>let-7e</i>Biologylcsh:RC254-282prognostic biomarkers:Phenomena and Processes::Genetic Phenomena::Genetic Processes::Gene Expression [Medical Subject Headings]miR-550:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]:Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Hydrolases::Peptide Hydrolases::Endopeptidases::Cysteine Endopeptidases::Caspases::Caspases Effector::Caspase 3 [Medical Subject Headings]microRNAGene expressionmedicine:Chemicals and Drugs::Biological Factors::Biological Markers [Medical Subject Headings]Mirna profilingGastrointestinal stromal tumors:Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Paraffin [Medical Subject Headings]GeneACVR1B:Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms Connective and Soft Tissue::Neoplasms Connective Tissue::Gastrointestinal Stromal Tumors [Medical Subject Headings]MicroARNsGiSTTumores del estroma gastrointestinalPronósticoMicroRNAlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePrognosislet-7e:Chemicals and Drugs::Nucleic Acids Nucleotides and Nucleosides::Antisense Elements (Genetics)::RNA Antisense::MicroRNAs [Medical Subject Headings]BiomarcadoresOncologyPrognostic biomarkersCaspase-3<i>miR-550</i>Gene chip analysisCancer research:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis [Medical Subject Headings]Target genesSarcomaGIST
researchProduct

Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab

2015

International audience; Natalizumab (NTZ), a monoclonal antibody recognizing the alpha4 integrin chain, has been approved for the treatment of active multiple sclerosis, but expose to the onset of a rare side effect, progressive multifocal leukoencephalopathy (PML). Estimating the individual risk of PML in NTZ-treated patients is a major challenge, and therapeutic strategies are mainly guided by the overall PML risk assessed by identified risk factors: JC virus (JCV) seropositivity, treatment duration (with peak incidence after 24 months), and the previous use of immunosuppressive therapies. Given that this stratification does not yet allow a precise individual prediction of PML, other pred…

lcsh:Immunologic diseases. Allergy[SDV.IMM] Life Sciences [q-bio]/ImmunologySide effectmedicine.drug_classvirusesImmunologyJC virusReview Articlerisk stratificationCD11aJC virusmultiple sclerosismedicine.disease_causeMonoclonal antibodyCD49dprogressive multifocal leukoencephalopathyNatalizumabeffector memory T-cellst effector memory cellsImmunology and AllergyMedicineselectinPMLbusiness.industryMultiple sclerosisProgressive multifocal leukoencephalopathyvirus diseasesmedicine.disease3. Good healthJCVImmunologySelectins[SDV.IMM]Life Sciences [q-bio]/Immunologylcsh:RC581-607businessmedicine.drugFrontiers in Immunology
researchProduct

The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies.

2021

Since the approval of the first monoclonal antibody (mAb) in 1986, a huge effort has been made to guarantee safety and efficacy of therapeutic mAbs. As of July 2021, 118 mAbs are approved for the European market for a broad range of clinical indications. In order to ensure clinical efficacy and safety aspects, (pre-)clinical experimental approaches evaluate the respective modes of action (MoA). In addition to antigen-specificity including binding affinity and -avidity, MoA comprise Fc-mediated effector functions such as antibody dependent cellular cytotoxicity (ADCC) and the closely related antibody dependent cellular phagocytosis (ADCP). For this reason, a variety of cell-based assays have…

modes of action (MoA)GlycosylationQH301-705.5medicine.drug_classCellReceptors FcReviewBiologyMonoclonal antibodyCatalysisInorganic Chemistrychemistry.chemical_compoundMonoklonaler Antikörper ; effector function ; antibody dependent cellular phagocytosis (ADCP) ; therapeutic monoclonal antibodies (mAbs) ; Fcγ receptor (FcγR) ; modes of action (MoA) ; antibody dependent cellular cytotoxicity (ADCC)medicineAnimalsHumansAvidityClinical efficacyBiology (General)Physical and Theoretical ChemistryReceptorQD1-999Molecular BiologySpectroscopyAntibody-dependent cell-mediated cytotoxicityEffectortherapeutic monoclonal antibodies (mAbs)Organic ChemistryAntibody-Dependent Cell CytotoxicityAntibodies Monoclonalantibody dependent cellular phagocytosis (ADCP)General MedicineFcγ receptor (FcγR)Computer Science ApplicationsImmunoglobulin Fc Fragmentsantibody dependent cellular cytotoxicity (ADCC)Chemistrymedicine.anatomical_structurechemistryImmunologyImmunotherapyeffector functionInternational journal of molecular sciences
researchProduct

Evolutionary Dynamics of Pathoadaptation Revealed by Three Independent Acquisitions of the VirB/D4 Type IV Secretion System in Bartonella

2017

The α-proteobacterial genus Bartonella comprises a group of ubiquitous mammalian pathogens that are studied as a model for the evolution of bacterial pathogenesis. Vast abundance of two particular phylogenetic lineages of Bartonella had been linked to enhanced host adaptability enabled by lineage-specific acquisition of a VirB/D4 type IV secretion system (T4SS) and parallel evolution of complex effector repertoires. However, the limited availability of genome sequences from one of those lineages as well as other, remote branches of Bartonella has so far hampered comprehensive understanding of how the VirB/D4 T4SS and its effectors called Beps have shaped Bartonella evolution. Here, we repor…

parallel evolution0301 basic medicineBartonellaAMPylation; bacterial effector; filamentation induced by cAMP; parallel evolutionVirulence FactorsIn silico030106 microbiologyBiologyfilamentation induced by cAMPGenomeEvolution MolecularType IV Secretion Systems03 medical and health sciencesBacterial ProteinsBartonella InfectionsGeneticsAMPylationHumansEvolutionary dynamicsBacterial Secretion SystemsPhylogenyEcology Evolution Behavior and SystematicsPhylogenetic treeEffectorbiology.organism_classificationbacterial effectorVirology030104 developmental biologyEvolutionary biologyFilamentation induced by cAMP; AMPylation; Parallel evolution; Bacterial effectorHost-Pathogen InteractionsParallel evolutionAdaptationBartonellaResearch Article
researchProduct

Consensus nomenclature for CD8(+) T cell phenotypes in cancer

2015

International audience; Whereas preclinical investigations and clinical studies have established that CD8+ T cells can profoundly affect cancer progression, the underlying mechanisms are still elusive. Challenging the prevalent view that the beneficial effect of CD8+ T cells in cancer is solely attributable to their cytotoxic activity, several reports have indicated that the ability of CD8+ T cells to promote tumor regression is dependent on their cytokine secretion profile and their ability to self-renew. Evidence has also shown that the tumor microenvironment can disarm CD8+ T cell immunity, leading to the emergence of dysfunctional CD8+ T cells. The existence of different types of CD8+ T…

senescenceT cellOncology and CarcinogenesisImmunology[SDV.CAN]Life Sciences [q-bio]/CancerBiologyCD8+ T cellsIFN gammaanergy03 medical and health sciencesstemness0302 clinical medicineImmune system[SDV.CAN] Life Sciences [q-bio]/Cancerexhaustionmedicine2.1 Biological and endogenous factorsImmunology and AllergyCytotoxic T cellAetiologyPoint of ViewCancer030304 developmental biologyCD8+ T cells; IFNγ; anergy; anticancer immunity; cytotoxicity; effector; exhaustion; senescence; stemness0303 health sciencesTumor microenvironmentCD8(+) T cellsCancermedicine.diseasePhenotype3. Good healthanticancer immunitymedicine.anatomical_structureeffectorOncologyImmunologycytotoxicityCytokine secretionCD8030215 immunologyIFNγ
researchProduct